PRECISION BIOSCIENCES INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
PRECISION BIOSCIENCES INC (DTIL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $270.63 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2026-03-31 was $274.66, a 2.33% decline year-over-year.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $281.20, a 12.06% increase year-over-year.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $250.94, a 2807.76% increase year-over-year.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $8.63, a 13.70% decline year-over-year.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $113.02, a 31.93% decline from fiscal 2024.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $166.04, a 25.00% decline from fiscal 2023.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $221.38, a 14.76% decline from fiscal 2022.
- PRECISION BIOSCIENCES INC share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $259.72, a 2539.43% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $270.63 10-Q · filed 2026-08-06 | ||||
| 2026-03-31 | $274.66 10-Q · filed 2026-05-05 | ||||
| 2025-12-31 | $113.02 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $112.62 10-Q · filed 2025-11-03 | ||||
| 2025-06-30 | $112.13 10-Q · filed 2025-08-07 | ||||
| 2025-03-31 | $281.20 10-Q · filed 2025-05-15 | ||||
| 2024-12-31 | $166.04 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $229.09 10-Q · filed 2024-11-04 | ||||
| 2024-06-30 | $233.85 10-Q · filed 2024-08-01 | ||||
| 2024-03-31 | $250.94 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $221.38 10-K · filed 2025-03-26 | ||||
| 2023-09-30 | $7.35 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | $8.47 10-Q · filed 2023-08-04 | ||||
| 2023-03-31 | $8.63 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $259.72 10-K · filed 2024-03-27 | $8.66 10-K · filed 2023-03-09 | |||
| 2022-09-30 | $9.65 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $9.73 10-Q · filed 2022-08-08 | ||||
| 2022-03-31 | $10.00 10-Q · filed 2022-05-09 | ||||
| 2021-12-31 | $9.84 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | $10.18 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $10.20 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $10.92 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $8.17 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $7.75 10-Q · filed 2020-11-10 | ||||
| 2020-06-30 | $7.76 10-Q · filed 2020-08-13 | ||||
| 2020-03-31 | $7.99 10-Q · filed 2020-05-15 | ||||
| 2019-12-31 | $10.47 10-K · filed 2021-03-18 | ||||
| 2019-09-30 | $10.46 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $9.80 10-Q · filed 2019-08-14 | ||||
| 2019-03-31 | $9.80 10-Q · filed 2019-04-29 | ||||
| 2018-12-31 | $2.01 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |